CD274 and hepatocellular carcinoma: Prospective studies incorporating pre-treatment biomarker analysis are warranted to optimize patient selection for combined locoregional and systemic therapies, as biomarker-driven approaches, such as PD-L1 staining or T-cell infiltration assessment, have shown promise in predicting response to immune checkpoint inhibitors in HCC (33).